The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
暂无分享,去创建一个
D. Wickerham | N. Wolmark | H. Bear | S. Anderson | Ann M Brown | Roy E. Smith | E. Mamounas | B. Fisher | R. Margolese | Heather Theoret | A. Soran | E. Mamounas | A. Brown | Harry D. Bear | H. Bear
[1] H. Skipper,et al. Kinetics of mammary tumor cell growth and implications for therapy , 1971, Cancer.
[2] R. Simon,et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. , 1978, The New England journal of medicine.
[3] G. Bonadonna,et al. Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. , 1981, Cancer clinical trials.
[4] G. Hortobagyi,et al. Multimodal treatment of locoregionally advanced breast cancer , 1983, Cancer.
[5] S. Steinberg,et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. , 1987, Cancer research.
[6] A. Korzun,et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Hortobagyi,et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy , 1988, Cancer.
[8] G. Hortobagyi,et al. Comprehensive management of locally advanced breast cancer , 1990, Cancer.
[9] L. Mauriac,et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] G. Hortobagyi,et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.
[11] M. Bissery,et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. , 1991, Cancer research.
[12] B. Asselain,et al. Neoadjuvant chemotherapy in operable breast cancer. , 1991, European journal of cancer.
[13] G. Hortobagyi,et al. Feasibility of breast‐conservation surgery after induction chemotherapy for locally advanced breast carcinoma , 1992, Cancer.
[14] C. Hudis,et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Dirk Schrijvers,et al. Coping with toxicities of docetaxel (TaxotereTM) , 1993 .
[16] R. Demicheli,et al. Activity of taxol (T) by 3 h infusion in breast cancer patients (pts) with clinical resistance to anthracyclines (A) , 1993 .
[17] C. Lipschultz,et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. , 1993, British Journal of Cancer.
[18] T. Postma,et al. High-dose taxol (HDT) with G-CSF in patients with advanced breast cancer (ABC) refractory to anthracycline (ANT) therapy , 1993 .
[19] R E Wittes,et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Calais,et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm , 1994, Cancer.
[21] B. Asselain,et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.
[22] M. Piccart,et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] G. Schwartz,et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast , 1994, Cancer.
[24] F. Cognetti,et al. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. , 1995, Journal of the American College of Surgeons.
[25] M. Christian,et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Caraceni,et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. , 1995, Journal of the National Cancer Institute.
[27] C. Hudis,et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] T. Powles,et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P M Ravdin,et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Hudis,et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] D A Podoloff,et al. Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] B. Asselain,et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. , 1995, European journal of cancer.
[33] V. Valero,et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] C. Hudis,et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] G. Fountzilas,et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. , 1996, European journal of cancer.
[36] K. Gelmon,et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] L. Norton,et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Coindre,et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.
[39] W. Gradishar. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. , 1997, Oncology.
[40] B. Leone,et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1998, The cancer journal from Scientific American.
[41] F. Kwiatkowski,et al. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. , 1998, American journal of clinical oncology.
[42] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. Coombes,et al. Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. , 1998, European journal of cancer.
[44] T. Powles,et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] H. Bear. Indications for neoadjuvant chemotherapy for breast cancer. , 1998, Seminars in Oncology.
[47] G. Hortobagyi,et al. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review). , 1999, International journal of oncology.
[48] G. Hortobagyi,et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] G. Sledge,et al. Taxanes in the treatment of breast cancer: a prodigy comes of age. , 1999, Cancer investigation.
[50] W. McCaskill-Stevens,et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] G. MacGrogan,et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] G. Hortobagyi,et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer , 2000, The Lancet.
[54] C. V. D. van de Velde,et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] W. Eiermann,et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] M. Buyse,et al. Taxanes in the adjuvant treatment of breast cancer: why not yet? , 2001, Journal of the National Cancer Institute. Monographs.
[57] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[58] A. Hutcheon,et al. Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: A randomised controlled trial , 2001 .
[59] Baljit Singh,et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. , 2003, Clinical Cancer Research.
[60] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] S. Schraub,et al. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] J. Blohmer,et al. Primary endpoint analysis of the GEPARDUO study: Comparing dose-dense with sequential adriamycin/docetaxel combination as preoperative chemotherapy (PCHT) in operable breast cancer (T2-3, N0-2, M0) , 2003 .